Shareholder Alert: Robbins LLP Announces It Is Investigating Gossamer Bio, Inc. (GOSS) on Behalf of Shareholders
April 08 2020 - 2:46PM
Business Wire
Shareholder rights law firm Robbins LLP informs shareholders it
is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) for potential
violations of federal securities laws and breaches of fiduciary
duty by its board members and executive officers. In its initial
public offering, Gossamer offered approximately 19.8 million shares
at $19.00 per share, raising gross proceeds of $317.4 million.
Gossamer's leading product is its GB001 drug, which is a DP2
antagonist drug for the treatment of asthma. However, on December
16, 2019, Novartis announced it was terminating the development of
its similar DP2 antagonist drug for asthma after it failed a pair
of phase 3 clinical trials. On this news, Gossamer's stock
plummeted 37% to close at $15.96 per share, representing a 16%
decline from its IPO price.
If you suffered a loss as a result of Gossamer's misconduct,
click here.
Gossamer Bio, Inc. (GOSS) Shareholders Have Legal
Options
Contact us to learn more: Leo Kandinov (800) 350-6003
LKandinov@robbinsllp.com Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional
investors in shareholder derivative and securities class action
lawsuits, and has helped its clients realize more than $1 billion
of value for themselves and the companies in which they have
invested. Click here to receive free alerts from Stock Watch when
companies engage in wrongdoing.
Attorney Advertising. Past results do not guarantee a similar
outcome.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200408005672/en/
Leonid Kandinov Robbins LLP 5040 Shoreham Place San Diego, CA
92122 LKandinov@robbinsllp.com (619) 525-3990 or Toll Free (800)
350-6003 www.robbinsllp.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jul 2023 to Jul 2024